The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 6,809,585 | 357,271 | SH | SOLE | 357,271 | 0 | 0 | |||
AMYLYX PHARMACEUTICALS INC | COM | 03237H101 | 4,059,379 | 275,773 | SH | SOLE | 275,773 | 0 | 0 | |||
APELLIS PHARMACEUTICALS INC | COM | 03753U106 | 8,979,000 | 150,000 | SH | SOLE | 150,000 | 0 | 0 | |||
ARGENX SE - ADR | SPONSORED ADR | 04016X101 | 13,315,050 | 35,000 | SH | SOLE | 35,000 | 0 | 0 | |||
AVADEL PHARMACEUTICALS-ADR | SPONSORED ADR | 05337M104 | 4,900,148 | 347,036 | SH | SOLE | 347,036 | 0 | 0 | |||
AXSOME THERAPEUTICS INC | COM | 05464T104 | 8,027,607 | 100,862 | SH | SOLE | 100,862 | 0 | 0 | |||
COMPASS THERAPEUTICS INC | COM | 20454B104 | 1,302,023 | 834,630 | SH | SOLE | 834,630 | 0 | 0 | |||
CONTEXT THERAPEUTICS INC | COM | 21077P108 | 820,325 | 725,951 | SH | SOLE | 725,951 | 0 | 0 | |||
CYMABAY THERAPEUTICS INC | COM | 23257D103 | 11,572,336 | 489,938 | SH | SOLE | 489,938 | 0 | 0 | |||
GERON CORP | COM | 374163103 | 6,270,158 | 2,971,639 | SH | SOLE | 2,971,639 | 0 | 0 | |||
HARPOON THERAPEUTICS INC | COM NEW | 41358P205 | 4,870,908 | 428,400 | SH | SOLE | 428,400 | 0 | 0 | |||
INTRA-CELLULAR THERAPIES INC | COM | 46116X101 | 10,123,344 | 141,348 | SH | SOLE | 141,348 | 0 | 0 | |||
JASPER THERAPEUTICS INC | COM | 471871103 | 28,871,522 | 3,659,255 | SH | SOLE | 3,659,255 | 0 | 0 | |||
MEDAVAIL HOLDINGS INC | COM NEW | 58406B202 | 529,358 | 117,897 | SH | SOLE | 117,897 | 0 | 0 | |||
MERUS NV | COM | N5749R100 | 7,560,383 | 274,923 | SH | SOLE | 274,923 | 0 | 0 | |||
MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 61559X104 | 8,664,697 | 143,479 | SH | SOLE | 143,479 | 0 | 0 | |||
AMBRX BIOPHARMA INC | COM | 641871108 | 5,487,854 | 385,383 | SH | SOLE | 385,383 | 0 | 0 | |||
OLEMA PHARMACEUTICALS INC | COM | 68062P106 | 9,246,261 | 659,035 | SH | SOLE | 659,035 | 0 | 0 | |||
PRAXIS PRECISION MEDICINES I | COM NEW | 74006W207 | 1,569,047 | 70,424 | SH | SOLE | 70,424 | 0 | 0 | |||
PROMIS NEUROSCIENCES INC | COM NEW | 74346M406 | 1,226,675 | 1,066,674 | SH | SOLE | 1,066,674 | 0 | 0 | |||
SOLENO THERAPEUTICS INC | COM | 834203309 | 12,475,488 | 309,950 | SH | SOLE | 309,950 | 0 | 0 | |||
XENON PHARMACEUTICALS INC | COM | 98420N105 | 11,144,724 | 241,961 | SH | SOLE | 241,961 | 0 | 0 |